Outlook Therapeutics, Inc. (OTLK)

Outlook Therapeutics is building its U.S. commercial organization for LYTENAVA, following FDA approval for wet age-related macular degeneration. Recent company announcements focused on commercial leadership, finance infrastructure, and international launches, while prior results showed continued losses and substantial funding needs. OTLK was up 1.12% today on a full-day basisas of November 10, 2026.